Highlight
– Once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) among people with overweight or obesity and established cardiovascular disease but no diabetes in the SELECT trial.
– The cardioprotective effect was consistent across baseline weight and waist circumference categories and was not fully explained by weight loss.
– Reduction in waist circumference accounted for approximately one-third of the observed MACE reduction; the majority of the benefit appears mediated by mechanisms beyond adiposity change.
